VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) - Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
- Wells Fargo Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 4 at 8:45 am Eastern Time (ET) in Boston, MA.
- Morgan Stanley 22nd Annual Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 5 at 7:00 am ET in New York, NY.
- H.C. Wainwright 26th Annual Global Investment Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 10 at 11:00 am ET in New York, NY.
- 2024 Cantor Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 18 at 3:05 pm ET in New York, NY.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
Related Links
-
Zymeworks Announces Participation in Upcoming Investor ConferencesVANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) - Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diver2024-08-23
-
消散的暑气迎接初秋 用美食调整身心状态时间一晃而逝,8月末的夏末,每天的清晨和傍晚也能明显地感受到空气中的热浪消散了很多,但是在中午和下午,却依旧太阳高照,似乎是夏天依旧不愿意告别,因为热意肆意,人也2024-08-23
-
加速AI规模应用,释放企业新质生产力,IBM中国企业级AI巅峰论坛成功举办北京2024年8月22日 -- 今天,IBM中国企业级 AI巅峰论坛在南京成功举行,IBM亚太区总经理Hans Dekkers、IBM 大中华区董事长、总经理陈旭东、IBM 咨询大中华区总裁2024-08-23
-
数字华章 博主亲证,WhatsApp拉群营销,国际业务新神器WS作为数字时代的探索者,我亲眼见证了WhatsApp拉群营销工具如何成为国际业务的神来之笔。它跨越地域界限,让我轻松触达全球潜在客户,构建起无国界的商业网络。在群组2024-08-22
-
广告效果迷雾散,WhatsApp拉群显真章WS曾几何时,他深陷广告效果难以衡量的困境,每一分投入都似石沉大海,难以捉摸回报。然而,自从拥抱WhatsApp拉群营销工具,一切豁然开朗。实时监测功能,如同明灯照亮前行之2024-08-22